Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors

Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors

WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation today
announced that it has elected to its Board of Directors John G. Cox, Executive
Vice President of Pharmaceutical Operations & Technology for Biogen Idec Inc.,
a leading biopharmaceutical company. Mr. Cox has over 20 years of
biopharmaceutical manufacturing experience and has supported the commercial
launches of a number of major biologic drugs. He has a track record of
implementing process changes to maximize manufacturing flexibility and
throughput; this includes playing a leading role in creating the vision for
Biogen Idec's "Future Factory," which aims to utilize disposable technology
platforms. Separately, the Company announced that at year end, Earl Henry,
M.D. will retire from the Repligen Board position that he has held since 2007.

"Mr. Cox's experience and his perspective as an end user of the products
developed and marketed by Repligen make him ideally suited to provide
strategic guidance to our Company, and we are pleased to welcome him as an
important addition to our Board," said Walter C. Herlihy, Ph.D., President and
Chief Executive Officer of Repligen. "We also sincerely thank Dr. Henry for
his many contributions to Repligen; in particular, his medical expertise was
invaluable while the Company was active in the clinical development of
therapeutics."

John Cox joined Biogen Idec in 2003 and has held multiple roles of increasing
responsibility in the areas of manufacturing and technical operations. Mr. Cox
has served as Executive Vice President of Pharmaceutical Operations &
Technology since June 2010. He has also served as Senior Vice President of
Technical Operations, Senior Vice President of Global Manufacturing, Vice
President of Manufacturing, General Manager of Biogen Idec's operations in
Research Triangle Park, North Carolina, and Director of Manufacturing. From
2000 to 2003, Mr. Cox held a number of senior operational roles at Covance
Biotech (a contract research organization acquired by Diosynth) where he
worked in technology transfer, validation and purification. From 1993 to 2000,
he focused on the same areas at American Home Products Corporation, now the
Wyeth, LLC subsidiary of Pfizer Inc. Mr. Cox received a Bachelors of Science
degree in biology from Arizona State University, a Masters of Science degree
in cell biology from California State University and a Masters of Business
Administration in finance degree from the University of Michigan.

About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the
development, production and commercialization of high-value consumable
products used in the process of manufacturing biological drugs. Our
bioprocessing products are sold to major life sciences and biopharmaceutical
companies worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to separate and purify monoclonal antibody therapeutics. We also
supply several growth factor products used to increase cell culture
productivity during the fermentation stage of drug manufacturing. In addition,
we have developed and market our OPUS® line of pre-packed "plug-and-play"
chromatography columns, and we provide test kits to ensure final product
quality. Repligen's corporate headquarters are in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release may contain forward-looking statements within the meaning
of the federal securities laws. Investors are cautioned that statements in
this press release which are not strictly historical statements including,
without limitation, statements identified by words like "believe," "expect,"
"may," "will," "should," "seek," or "could" and similar expressions,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including risks discussed from
time to time in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.

CONTACT: Repligen Corporation
         Sondra Newman
         Director Investor Relations
         (781) 419-1881
         snewman@repligen.com